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Biophysical approaches for the study of
interactions between molecular chaperones
and protein aggregates
Maya A. Wright, Francesco A. Aprile, Paolo Arosio, Michele Vendruscolo,
Christopher M. Dobson and Tuomas P. J. Knowles*
Molecular chaperones are key components of the arsenal of cellular defence mechanisms active against
protein aggregation. In addition to their established role in assisting protein folding, increasing evidence
indicates that molecular chaperones are able to protect against a range of potentially damaging aspects of
protein behaviour, including misfolding and aggregation events that can result in the generation of aberrant
protein assemblies whose formation is implicated in the onset and progression of neurodegenerative
disorders such as Alzheimer’s and Parkinson’s diseases. The interactions between molecular chaperones
and diﬀerent amyloidogenic protein species are diﬃcult to study owing to the inherent heterogeneity of
the aggregation process as well as the dynamic nature of molecular chaperones under physiological
conditions. As a consequence, understanding the detailed microscopic mechanisms underlying the nature
and means of inhibition of aggregate formation remains challenging yet is a key objective for protein
biophysics. In this review, we discuss recent results from biophysical studies on the interactions between
molecular chaperones and protein aggregates. In particular, we focus on the insights gained from current
experimental techniques into the dynamics of the oligomerisation process of molecular chaperones, and
highlight the opportunities that future biophysical approaches have in advancing our understanding of the
great variety of biological functions of this important class of proteins.
1 Protein folding and aggregation
Proteins take part in virtually all of the key molecular processes
in living organisms by interacting with a wide range of bio-
molecules, including other proteins. In order to function properly,
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proteins generally have to fold into specific three-dimensional
structures known as native states. The folding of proteins into
these conformations is, at least at low concentrations, a spon-
taneous self-assembly process in which their free energy is
minimised,1 through the optimization of intramolecular inter-
actions within the protein chain as well as protein–solvent
interactions.1–3 In particular, it is generally favourable for
amino acid residues with hydrophobic side chains to be buried
within the folded native structure, shielded from the aqueous
cell medium.3 However, at higher concentrations, such as those
found in the cellular environment, the native state can become
metastable relative to self-assembly into aggregates.4–6 In addi-
tion, incompletely formed nascent protein chains emerging
from the ribosome are typically exposed to the highly crowded
cellular environment in an unfolded state for long periods with
respect to the time required for their folding.7 Indeed, slow
rates of codon translation significantly increase the chance of
misfolding through inappropriate intramolecular interactions
between hydrophobic amino acid residues on nascent chains, and
between nascent chains and other proteins or biomolecules
within the cytoplasm.7,8 In order to counteract proteinmisfolding,
cells contain a range of protective mechanisms, notably molecular
chaperones, which assist proteins in attaining their native
conformations. However, some proteins escape these control
mechanisms and form partially folded or misfolded states
which lack their intended biological function and which are
particularly prone to aggregation.7
Protein aggregates can range from amorphous species to
highly ordered b-sheet rich amyloid fibrils. Amorphous aggre-
gates are largely disordered deposits and can be degraded readily
within the cell,9,10 whereas amyloid aggregates are highly persis-
tent and stable assemblies of proteins. The formation of such
aggregates is associated with the onset and development of a
range of disorders such as Alzheimer’s and Parkinson’s diseases,
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type II diabetes, and the formation of eye lens cataracts.11–14
The mechanism by which soluble monomeric proteins assem-
ble into fibrils involves several distinct microscopic processes.15
Typically, protein monomers first assemble into soluble low
molecular weight oligomers through primary nucleation. These
oligomers then elongate via monomer addition, leading to the
formation of long and highly organised mature fibrils. Amyloid
formation is accelerated by fragmentation of existing fibrils and
other forms of secondary events, for example secondary nuclea-
tion in which the surfaces of mature fibrils catalyse the nuclea-
tion of monomers as a feedback system that results in the
production of new aggregates.15,16 To counteract the numerous
pathways that lead to the formation of fibrils, it is becoming
increasingly clear that cells utilise molecular chaperones as a
front line defense mechanism against amyloid formation.
2 Molecular chaperones assist in
protein folding
The cell and its extracellular environment possess a complex
system of molecular chaperones that intervene in various steps
along the protein folding pathways. The first molecular chaper-
ones encountered by proteins are those associated with the
ribosome.7 In eukaryotes, such molecular chaperones include
the nascent chain-associated complex (NAC) and the ribosome-
associated complex (RAC), which are bound directly to the
ribosome and dynamically interact with nascent chains during
protein biogenesis.7,17–19 NAC exists as a heterodimer of a and
b components, and it is thought to shield hydrophobic residues
on protein chains emerging from the ribosome.7,18,20 RAC is a
multiprotein complex that stabilises nascent chains and, with the
help of other downstream molecular chaperones, assists around
20% of proteins in attaining their native conformations.17 Protein
chains that cannot reach their native states with the help of NAC
and RAC continue to elongate, and encounter the nonribosome-
binding Hsp70/Hsp40 system which acts further downstream in
the protein folding process.21 In an ATP-dependent cycle, Hsp70
rapidly binds and unbinds to hydrophobic patches on nascent
protein chains to prevent inappropriate interactions, and to
decrease the concentration of aggregation prone unfolded
species.7 During this process, Hsp40, a 40 kDa heat shock
protein, acts as a cochaperone that increases the efficiency of
the ATP binding and release cycle.22 Finally, upon release from
the ribosome, protein chains that still need assistance in folding
proceed to interact with the TriC (TCP1 ring complex) or Hsp90
chaperone system.17,23 TriC operates by encapsulating non-
native protein chains in a chamber and providing a shielded
environment in which they can fold undisturbed.23
3 Molecular chaperones curtail
amyloid formation
The role that molecular chaperones play in assisting protein
folding has been studied extensively, and significant progress has
been made in elucidating the mechanisms involved, as described
in the previous section. However, increasing evidence indicates
that assisting nascent protein chains in reaching their native
conformations is just one of the many functions of molecular
chaperones (Fig. 1A). Indeed, several studies have shown that
molecular chaperones also play a more direct role in protecting
against protein aggregation by refolding non native proteins and
promoting disaggregation of misassembled proteins (Fig. 1B
and C), as well as inhibiting fibril formation by establishing inter-
actions with a variety of amyloidogenic species such as partially
folded intermediates, toxic oligomers, and mature amyloid fibrils
(Fig. 1D and E).24–34 For example, the extracellular molecular
chaperones a2-macroglobulin and clusterin have been shown to
interact with a variety of amyloidogenic proteins to inhibit the
formation of fibrils.35–37 At the same time, there exist many
different molecular chaperones that act predominantly inside
the cell to prevent a range of aberrant processes, including those
associated with the progression of neurodegenerative diseases.38
In the following we discuss specifically the function of two
ubiquitous types of intracellular eukaryotic molecular chaper-
ones, Hsp70 and aB-crystallin (aBC), which have been popular
targets of biophysical characterisation studies because of their
protective role against protein aggregation and their oligomer-
isation properties.
Human Hsp70 has been shown to inhibit, at substoichio-
metric ratios, the formation of a-synuclein and amyloid b(1–42)
peptide aggregates (Ab42) which are associated with Parkinson’s
and Alzheimer’s diseases, respectively.33,39–41 Such inhibitory
action has not only been observed in human cells, but also
in yeast where Hsp70 family members have been shown to
increase the lag time in the aggregation of Ure2p, a prion
protein.42 Although it has been proposed that Hsp70 acts by
binding to aggregation-prone monomeric proteins to suppress
nucleation in human cells,33 this has not been experimentally
confirmed and the mechanism of chaperone action still remains
largely unknown.
Members of the Hsp70 family are also known for their ability
to reverse the formation of protein aggregates with the assistance
of co-chaperones both in vivo and in vitro.24–30 For example, the
Hsp104, Hsp70, and Hsp40 systems have been shown to disaggre-
gate and refold firefly luciferase, b-galactosidase clusters,25 and
heat denatured green fluorescent protein (GFP).29 The proposed
mechanism of disaggregation involves first the identification
of protein aggregates by Hsp70 and Hsp40 in an ATP-
dependent process. Then, Hsp70 and Hsp40 bind and extract
individual misfolded protein molecules from the surface of
these clusters.24,29,43 Subsequently, the extracted misfolded
molecule is translocated across ClpB (an Hsp104 homologue),
which allows it to unfold and exit into the cytoplasm, where it
achieves its native conformation spontaneously or with the
help of other molecular chaperones.24,27,43 Disaggregation by
Hsp104 has been observed for both amorphous and amyloid
aggregates.24,44 The variety of molecular chaperone functions
that Hsp70 possesses, including preventing protein misfolding,
inhibiting amyloid fibril growth, and resolubilizing aggregates,
makes it a key part of the network of molecular defences in
place for assisting cells in combating protein aggregation.
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Another crucial molecular chaperone known for its ubiquity
and important biological function in preventing amyloid for-
mation is aB-crystallin (aBC). The molecular chaperone aBC is
a small heat shock protein found in almost every tissue,45 and
is expressed at particularly high concentrations within the eye
lens where it serves to maintain lens transparency.46 Many
studies31,32,34,47,48 have reported that aBC binds to a wide range
of proteins to inhibit amyloid formation, including disease
associated proteins such as a-synuclein,9,32,49 insulin,50 and
Ab.31,51 According to in vitro biophysical studies, the addition of
aBC to solutions of a-synuclein suppresses protein aggregation
both in its earliest growth stages and in later stages.49 The
mechanism of inhibition is unclear, although the results of
nuclear-magnetic resonance (NMR) spectroscopy studies suggest
that aBC is able to bind a-synuclein monomers.9,49 Electron
microscopy studies9 also detected the formation of amorphous
a-synuclein deposits in the presence of aBC, suggesting that aBC
might be able to direct pre-fibrillar a-synuclein species towards
alternative pathways leading to the formation of nontoxic and
biodegradable amorphous species.9,10
Although it is becoming increasingly evident that molecular
chaperones play a crucial protective role in counteracting
amyloid formation, the detailed molecular mechanisms under-
lying this inhibition process have not been elucidated owing to
the inherent heterogeneity of aggregating protein systems in
the presence of molecular chaperones, as well as the transient
nature of the biomolecular interactions involved.
4 Dynamic oligomeric states of
molecular chaperones
Under physiological conditions, many molecular chaperones,
including Hsp70s and small heat shock proteins, have a pro-
pensity to self-associate to form oligomers.52–56 The polydisper-
sity of molecular chaperones adds to the complexity of probing
molecular chaperone–substrate interactions. Generally, the
determination of the specific species interacting, the quantifi-
cation of their binding affinity, and the characterisation of the
population distribution and binding mechanism is difficult for
interacting heterogeneous systems. It is therefore of critical
importance to study the dynamics of molecular chaperone
systems separately to ensure that their self-assembly behaviour
can be taken into account when measuring specific interactions
of these molecules with their client proteins. Elucidation of the
oligomers involved in the suppression of protein aggregation is
likely to yield valuable information on the molecular basis of
chaperone action, the key interaction mechanisms involved,
Fig. 1 The roles of molecular chaperones (green) in protecting proteins from aggregation. Dotted arrows signify very slow processes. The section in
which each type of molecular chaperone function is discussed is labelled in italics. Molecular chaperones are able to (A) protect ribosome-bound nascent
chains and assist in co-translational folding, (B) rescue and refold unfolded, misfolded, or non native proteins released from the ribosome, (C) disaggregate
amorphous deposits, (D) interact with pre-fibrillar amyloidogenic proteins, and (E) bind tomature fibrils. However, the dynamic oligomeric states of molecular
chaperones (F) contribute greatly to the heterogeneity of chaperone-substrate systems by interacting with species present in all processes (A) through (E).
Partially adapted from ref. 24.
Feature Article ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
0 
A
ug
us
t 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
7/
12
/2
01
5 
12
:0
2:
29
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Chem. Commun., 2015, 51, 14425--14434 | 14429
and the target amyloidogenic species. These oligomeric states of
molecular chaperones have, however, proved to be particularly
difficult to characterise because of the continuous interconver-
sions between a variety of higher molecular weight species,
ranging typically from dimers to dodecamers.55,56
For example, under physiological conditions in vitro, mem-
bers of the Hsp70 family have been shown to exist as a series of
monomeric, dimeric, trimeric, and higher order oligomeric
species in reversible dynamic equilibrium. (Fig. 2A).52 Hsp70
is known to be particularly active in its monomeric form, and
that its oligomerisation is regulated by the nucleotide state of
chaperone–substrate binding.52,57,58,66 In contrast, aBC typically
forms polyhedral oligomers with sizes ranging from 10-mers
to 40-mers, with the most dominant species shifting between
28–32 subunits depending on the pH and solvent conditions
(Fig. 2B).53,67–70 Although many studies have attempted to
elucidate the molecular basis of aBC action,72–75 the effect that
aBC polydispersity has on its molecular chaperone function
remains unclear, with some studies suggesting that aA- and
aB-crystallin exhibit maximum activity in their suboligomeric
forms,59–64 while others have shown that intramolecularly
cross-linked a-crystallin oligomers are still chaperone active.65
Since it is clear that the ability of molecular chaperones to bind
substrates is influenced by their oligomerisation state, elucidat-
ing the dynamic behaviour of molecular chaperones is likely
to be a crucial step in characterising their amyloid inhibition
mechanisms and the identity of the active oligomeric species
involved in their chaperone function.
5 Experimental challenges and
biophysical approaches for the study
of the mechanisms of molecular
chaperone action
The polydispersity of both molecular chaperones and the variety
of species generated during protein aggregation makes it challen-
ging to identify the specific interactions occurring between these
molecules. These two aspects of the problem are interconnected
and are diﬃcult to investigate separately. One way forward would
be the development of rapid, high-resolution biophysical techni-
ques capable of resolving the complete population of species
within chaperone–substrate systems as well as the interactions
occurring between the individual components present. Although
such efforts in developing novel techniques is still in progress,
several currently available biophysical approaches offer attractive
possibilities for the elucidation of the oligomeric distribution
of molecular chaperones as well as their interactions with
amyloidogenic species. In the following sections we give a brief
overview of a range of techniques used in the biophysical
characterisation of molecular chaperone oligomers and their
interactions with client proteins, and highlight in particular
how quantitative techniques have unveiled how molecular
chaperones target and bind directly to amyloid fibrils in order
to counteract aggregation. A summary of the various techni-
ques and their target species is reported in Table 1.
Several conventional experimental methods are available for
investigating the oligomeric populations of molecular chaper-
ones (Fig. 1F) including bulk techniques such as size-exclusion
chromatography (SEC), dynamic light scattering (DLS) and fluores-
cence correlation spectroscopy (FCS). SEC separates single species
within a heterogeneous solution according to their elution volumes,
and provides information on oligomeric molecular weight distri-
butions.82,83 This technique is one of the most common
approaches for investigating protein size distributions and
has been used to elucidate the oligomeric states of Hsp70.52
However, potential artefacts related to the interaction of bio-
molecules with the stationary phase of the column and sample
dilution during the measurement should be accounted for
during data analysis.
DLS and FCS allow non-invasive measurements of the diﬀu-
sion coeﬃcients of biomolecules, which in turn provide informa-
tion on their hydrodynamic radii. The diﬀusion of analyte species
is monitored as a function of time by recording light scattering
or fluorescence fluctuations of the molecules of interest.79,86,87
These techniques have proved to be particularly eﬀective in the
sizing of homogeneous mixtures. In contrast, the evaluation of
the distribution of sizes by these approaches is more diﬃcult,
since this requires the deconvolution of an average signal, which
is a diﬃcult inverse problem particularly susceptible to experi-
mental noise.80 In addition, in the case of DLS, the accurate
sizing of heterogeneous mixtures is complicated by the fact that the
average hydrodynamic radius is dominated by larger species owing
to the strong dependence of the scattering intensity on particle
radius, as described by the Rayleigh formalism.81 As a consequence,
Fig. 2 (A) Schematic illustration of the oligomerisation process of Hsp70.
Components of Hsp70 are shown as follows: nucleotide binding domain
(blue), substrate binding subdomain (red), helical lid subdomain (grey), and
interdomain linker (green). Under physiological conditions in vitro, Hsp70
exists in equilibrium between monomeric, dimeric, and higher order oligo-
meric species.52 Reproduced from ref. 52. (B) (i) Oligomeric population
distribution of aBC obtained by quantitative mass spectrometry measure-
ments.71 Reproduced from ref. 71. (ii) Modes of interaction between aBC
molecules. Intra-dimer interactions hold two aBC molecules together, and
inter-dimer interactions link adjacent dimeric subunits. The result is an
overall polyhedral aBC architecture. Reproduced from ref. 68.
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in the context of molecular chaperones, these techniques are
often used to supplement the results obtained by using other
biophysical methods, such as in studies probing Hsp70 self-
assembly and the interactions of Hsp70 with prion proteins.42,52
A more quantitative analysis of the dynamics of polydisperse
oligomeric species can be achieved using mass spectrometry
(MS).53,68,71 In particular, applications of ion mobility-mass
spectrometry (IM-MS) to the study of protein complexes and
amyloid oligomers in their intact, undissociated forms have
provided valuable information on quaternary protein structure
and topology.88,89 In addition, use of tandem MS and collision
induced dissociation (CID) has allowed the quantification
of the relative populations of oligomeric aBC as well as the
energetics involved in their self-assembly.53,68 Typically, hetero-
geneous protein samples have mass spectra with overlapping
peaks which arise from the diﬀerent species present, making it
diﬃcult to extract quantitative information.88 However, this
problem can be overcome using CID in which highly charged
monomeric species are dissociated from aggregates prior to
sample injection into the flight tube. This procedure allows the
deconvolution of peaks, since the highly charged dissociated
monomers give rise to a signal at low m/z whereas the comple-
mentary oligomer peaks occur at higherm/z.88 Although theseMS
techniques provide quantitative information on heterogeneous
protein systems, the change of phase of the sample from solution
to gas must be accounted for appropriately.
In terms of probing the interactions of molecular chaper-
ones with their client proteins in bulk (Fig. 1D and E), analytical
ultracentrifugation (AUC) is a useful method which allows
separation of biomolecules according to their sedimentation
coeﬃcients, providing crucial information about their mass
and size.76,77 A key advantage of AUC is that it is possible to
characterise the binding stoichiometry and distribution of mole-
cules in solution, including complexes of molecular chaperones
and amyloidogenic proteins. For example, AUC sedimentation
experiments have shown that aBC is able to bind directly to
mature protein fibrils at near stoichiometric ratios.31,32
Single molecule techniques have recently emerged as highly
eﬀective methods for monitoring the dynamics of individual
molecules in heterogeneous solutions without the need for
prior separation, making it ideal for the detection of molecular
chaperone interactions with prefibrillar species. Fluorescence
resonance energy transfer (FRET) imaging probes the inter-
action of biomolecules that are spatially located at a distance
shorter than 1–10 nm based on nonradiative energy transfer
from a donor molecule to an acceptor molecule.84,85 This method
therefore represents a powerful approach for detecting protein–
protein interactions, and has been used to elucidate key com-
plexes formed between both intra and extracellular molecular
chaperones with aggregated species of the disease associated
amyloid b(1–40) (Ab40) peptide.
37,38 The findings of these studies
show that both aBC and clusterin are able to form stable com-
plexes with Ab40 oligomers spanning a range of subunit numbers,
suggesting that sequestration of Ab40 oligomers by these mole-
cular chaperones plays a key role in the prevention of aberrant
aggregation processes.37,38
Solution- and solid-state NMR spectroscopy enable the
characterisation of protein conformations and allow the detection
of interactions between biomolecules.92 For example, an NMR
study on aBC and a-synuclein has shown that the addition of aBC
to a-synuclein fibril solutions shifts the monomer–fibril equili-
brium towards monomers.32 This result indicates that the binding
of aBC to fibrils leads to fibril disaggregation via weakening of
the interactions between adjacent a-synuclein molecules within
mature fibrils.32 In addition, NMR studies are often supplemented
by molecular dynamics simulations which give further insights
into the structure, topology, and dynamics of proteins.92,97–99
Small-angle X-ray scattering (SAXS) and small-angle neutron
scattering (SANS) are also highly eﬀective and established
methods for the structural characterisation of proteins in bulk.
These methods do not impose a molecular weight limit as in
solution NMR spectroscopy100 and allow solution-state measure-
ments to be made without the need for a crystalline sample.96
Since the static nature of these techniques makes the detec-
tion of transient biomolecular interactions diﬃcult,88,89 SAXS
and SANS are commonly applied for probing the structure of
fibrils and oligomers, rather than dynamic chaperone–fibril
interactions.9,101
Table 1 Biophysical techniques used to characterise the oligomeric states of molecular chaperones and their interactions with amyloidogenic proteins
Target Technique Experimental information Ref.
Molecular chaperone oligomers SEC Size distribution 52, 82 and 83
DLS Hydrodynamic radius 79–81
FCS Hydrodynamic radius 86 and 87
IM-MS Population distribution and bimolecular structure in the gas phase 68, 71, 88 and 89
Chaperone–protein interactions AUC Molecular weight distribution 31, 32, 76–78
sm-FRET Interactions between biomolecules in close proximity (1–10 nm) 37, 38, 84 and 85
NMR Solution-state: structure, interactions, and dynamics of biomolecules
Solid-state: structure of insoluble biomolecules
32 and 92–95
Fibril structure and chaperone
binding
SAXS & SANS Low-resolution protein structure in solution 96
Immuno-EM Structure and location of proteins in cells 31, 32, 90
Cryo-EM Structure of biomolecules, including amyloid fibrils and oligomeric proteins 67 and 91
Chaperone–fibril interactions QCM Molecular binding 50 and 83
SEC: size-exclusion chromatography, DLS: dynamic light scattering, FCS: fluorescence correlation spectroscopy, IM-MS: ion-mobility mass
spectrometry, AUC: analytical ultracentrifugation, sm-FRET: single-molecule fluorescence resonance energy transfer imaging, NMR: nuclear
magnetic resonance spectroscopy, SAXS: small-angle X-ray scattering, SANS: small-angle neutron scattering, immuno-EM: immuno-electron
microscopy, cryo-EM: cryo-electron microscopy, QCM: quartz-crystal microbalance.
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The techniques described above involve indirectly obtaining
the size or mass of biomolecules from the measurement of
their physical and chemical parameters such as sedimentation
coeﬃcient, diﬀusion coeﬃcient, elution volume, and collision
cross-section. The structure of complexes can also be visualised
directly by imaging. In this context, electron microscopy techni-
ques are commonly applied to the analysis of protein samples. In
particular, immuno-electronmicroscopy and cryo-electron micro-
scopy allow biomolecules to be imaged and provide a qualitative
analysis of the diﬀerent structures present, although quantifica-
tion of the relative amounts remains challenging to achieve
through this approach.90 For example, immuno-electron micro-
scopy studies show that the mode of binding between aBC and
mature a-synuclein and Ab42 fibrils involves attachment of aBC
along the long axis of the fibrils as well as to the fibril ends.31,32
This binding suggests that aBC inhibits fibril growth either by
capping the reactive ends of growing fibrils and preventing
elongation, or by deactivating sites which may catalyse secondary
nucleation along the length of the fibril.34,50 Cryo-electron
microscopy studies have been used to probe the quaternary
structure of aBC as well as the growth of Ab42 fibrils in the
presence of molecular chaperones.67,91
Quartz-crystal microbalance (QCM) and ThT fluorescence
studies have illuminated additional aspects of the binding of
molecular chaperones to fibrils. In QCM studies, protein fibril
seeds are deposited onto the surface of a microbalance and are
then exposed to a solution of protein monomers. The addition
of monomeric units to the fibril seeds induces a decrease in
oscillation frequency of the quartz balance. Highly sensitive
measurements on molecular chaperone binding can therefore
be achieved by recording the oscillation frequency as a function
of time.50,83 By applying this technique, it has been shown that
aBC is able to bind directly to insulin fibrils specifically during
the fibril elongation phase, thereby inhibiting the growth of
protein fibrils via monomer addition (Fig. 3A).31,32,50
ThT fluorescence studies are based on the enhanced quan-
tum yield of ThT dye upon binding to fibrils. The time evolution
of fibril formation can therefore be followed by recording the
Fig. 3 Examples of biophysical studies probing the interactions of molecular chaperones with amyloid fibrils. (A) QCM study on aBC binding to insulin
fibrils. The left panel shows how the mass changes as a function of time when fibril seeds are exposed to the following conditions: green (I): fibril seeds
are exposed initially to a solution of insulin; red (II): fibril seeds are then exposed to a solution of insulin and aBC, with aBC : insulin at 0.5 : 1; blue (III): fibril
seeds are exposed once again to a solution of insulin only. Since fibril elongation is inhibited even after removal of the aBC solution, this implies that aBC
binds directly to fibrils. Right panel: (top) Mass increase as a function of time under the three diﬀerent conditions (I), (II), and (III) shown in the left panel.
(Bottom) schematic illustration of (I) fibril exposure to protein monomers, (II) fibril exposure to monomers + molecular chaperones, (III) molecular
chaperones bound to fibrils. Adapted from ref. 50. (B) Immuno-electron microscopy image of the molecular chaperone Brichos bound directly to Ab42
fibrils. Reproduced from ref. 91. (C) ThT fluorescence study on Ab42 growth in the absence of Brichos and with increasing amounts of monomer equivalents
added at 10, 15, 35, 50, 75, and 100% from left (blue) to right (green). Dashed lines show the integrated rate law for Ab42 growth in the absence of Brichos
(blue), and the predicted reaction profile in which the rate constants for secondary nucleation processes are set to zero (green). Reproduced from ref. 91.
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fluorescence signal of ThT. Experiments performed in the
absence and presence of molecular chaperones provide evidence
of the capacity of these molecules to inhibit aggregation pro-
cesses. For instance, in a kinetic study conducted on Ab40 growth
seeded by Ab42 fibrils, a decrease in fluorescence signal was
observed in the presence of aBC, suggesting that the molecular
chaperones interact directly with fibril seeds.51 Interactions
between Hsp70 and a-synuclein seeds have been revealed in a
similar way.39
In addition to the experimental techniques described above,
analysis of chemical kinetics has emerged as a powerful tool for
complementing experimental characterisation and for provid-
ing insights into the microscopic mechanisms of molecular
chaperones acting against protein aggregation.102 This strategy
consists of monitoring the time evolution of fibril formation
(for example, by ThT fluorescence) at diﬀerent protein and
chaperone concentrations. The reaction profiles typically follow
a sigmoidal shape which results from a highly non-linear
combination of a series of microscopic events, including primary
nucleation, elongation, fragmentation, and secondary nuclea-
tion. The modification of a specific microscopic event aﬀects the
reaction profiles in a characteristic manner.102 Therefore, kinetic
analysis of the changes in the reaction profiles measured in the
absence and presence of diﬀerent concentrations of molecular
chaperones yields information on the specific protein species
targeted by molecular chaperones as well as the microscopic
steps which are aﬀected by such interactions. This method has
been implemented in studies on interactions between various
molecular chaperones and Ab42.
91,103 Kinetic analysis reveals
that the mechanism of action which best matches the change
in Ab42 aggregation profile in the absence and presence of the
molecular chaperone Brichos, a protein domain of approximately
100 residues, corresponds to the inhibition of secondary nucleation
processes through direct binding of Brichos to Ab42 fibrils (Fig. 3B
and C), which thereby suppresses the generation of toxic
oligomers.91 Similarly, it has been shown that the molecular
chaperone DNAJB6 inhibits Ab42 aggregation through suppres-
sing both primary nucleation and growth events.103
It is clear that a variety of biophysical methods are currently
available for probing molecular chaperone interactions with
their client proteins through all stages during the formation of
amyloid fibrils (Fig. 1D and E) as well as for investigating
molecular chaperone oligomerisation separately (Fig. 1F). Most
notably, quantitative biosensing techniques and applications of
the theoretical aspects of protein aggregation kinetics have
elucidated an important function of molecular chaperones,
which is to bind directly to amyloid fibrils in order to prevent
the proliferation of protein aggregates.31,32,50,91,103 This discovery
is a crucial step forward since, although the potent inhibitory
eﬀect that molecular chaperones have on fibril generation has
been well documented, the molecular mechanisms involved
were previously unknown. It is becoming increasingly recognised
that analysis of such systems using quantitative techniques
allows the identification of the specific aggregation events that
are inhibited as well as the key interactions involved, enhancing
our understanding of how molecular chaperones function in vivo.
Therefore, the development of novel quantitative biophysical
methods capable of detecting individual components of a
heterogeneous system of biomolecules under near physiological
conditions is likely to be of critical importance in advancing our
knowledge of molecular chaperone–protein interactions and the
roles that they play in preventing protein aggregation.
6 Conclusions
The eﬀects that molecular chaperones have on protein aggregation
are increasingly well understood and evidence has emerged that
they can protect against a wide variety of aberrant protein beha-
viour includingmisfolding and amyloid fibril formation processes.
However, the molecular basis of chaperone action and the specific
target protein species involved remain less well characterised for
many systems. Elucidating the exact roles that molecular chaper-
ones play in regulating protein aggregation is crucial for under-
standing the molecular events likely to be involved in the onset
and progression of protein misfolding diseases. In order to
address this problem and to advance our knowledge of chaperone
action, it has become apparent that a detailed analysis of the
oligomeric behaviour of molecular chaperones and their interac-
tions with amyloidogenic protein species represents a key objec-
tive for biophysical studies. Progress in this direction involves the
study of highly polydisperse systems in which multiple interac-
tions occur simultaneously, a situation which arises as a conse-
quence of the fact that molecular chaperones are commonly
present as a dynamic and heterogeneous ensemble of oligomers,
and are capable of interacting with a large variety of monomeric
and aggregated misfolded species. Use of biophysical techniques
for the characterisation of the oligomeric states of molecular
chaperones, both in isolation and in the presence of their
substrates, has yielded valuable insights into the molecular
mechanisms underlying their function. Current and future devel-
opments in biophysical methodologies have the potential to probe
increasingly complex and heterogeneous systems of aggregates of
client proteins and molecular chaperone oligomers, and to open
up the possibilities for their quantitative characterisation.
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